In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The GSK/Pfizer HIV Venture: Another Sign of Change?

Executive Summary

Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.

Related Content

Changing Pharma's Innovation DNA
Pharma: Serious About Change?
Open to Innovation: A Conversation with Johnson & Johnson Pharma R&D Chief Paul Stoffels
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Best of the Blog: IN VIVO, May/June 2009
Collaborating for Better R&D Productivity
GSK Tries to Mimic Real-World Biotech
Pfizer/Wyeth: Industrializing Pharma?
Pfizer Restructures for a More Flexible Future
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts